Intravenous Iron Therapy for the Treatment of Iron Deficiency Anemia: Ferric Carboxymaltose Vs Iron Sucrose
Background: Postpartum anemia effects every fourth women in India. Parenteral iron therapy in comparison to oral is much faster in correction of Hb level, and replenishment of iron stores with much better compliance. The two available preparations of parentral iron that is iron sucrose and ferric carboxymaltose were compared in the present study for safety and efficacy.
Methods: This prospective observational study was conducted in the department of obstetrics and gynecology (SRHU Dehradun Uttarakhand) for a period of 18 month. 180 women of iron deficiency anemia were divided into two groups. 100 mg of IV iron sucrose was given in multiple dose of 200mg on alternate day over a period of 10 days to one group. 1000 mg of IV ferric carboxymaltose was given a single dose to the 2nd group of 90 women. side effects and reactions were noted.
Results: Hb% and serum ferritin were done after 14 day of last injection the mean rise in HB in both groups were 1.71%( Group I) versus 3.20 % (Group II) serum ferritin levels was found significantly higher (p vol < 0.0001) in group II there were no serious adverse reactions in either group.
Conclusions: FCM proved its efficacy better than iron sucrose. short stay at hospitals, large dose were given at over with very few adverse reactions were the main advantage.
2. Cunninghum FG, Lenevo KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY, Haematological disorder. Editor. Williams obstetrics, 23rd edition. Philadelphia, McGraw Hil; 2010:1080.
3. Aggett P. Iron and women in the reproductive years. In: The British nutrition foundation’s task force, editors. iron: nutritional and physiological significance, 1st edition. London: Chapman Hall;1995:110-8.
4. World Health Organization. Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement. Geneva:WHO;1999.
5. Bodnar LM, Cogswell ME, Mc Donald. Have we forgotten the significance of postpartum iron deficiency? Am J Obstet Gynecol. 2005;193(1):36-44.
6. Perez EM, Hendricks MK, Beard JL, Murray KLE, Berg A, Tomlinson M, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutr. 2005;135(4): 850-5.
7. Silla LM, Zelmanowicz A, Mito I, Michalowski M, Hellwing T, Shilling MA, et al. High prevalence of anemia in children and adult women in an urban population in southern Brazil. PLOSONE. 2013; 8 (7):e68805.
8. Brugnara C, Beris P. Iron therapy. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of erythropoiesis, erythrocytes and iron metabolism. Paris: European School of Haematology; 2009. p. 512–28.6.
9. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1299–307.7.
10. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18(2):319–328.
11. DeGruchy’s clinical hematology in clinical practice. Hypochromic anemias: Iron deficiency and Sideroblastic. [ eds. Firkin F, Perington D, Rush B, Chesterman C.] Blackwell Science Publication. Fifth edition. 1989. p 31-60.
12. Dhanani J V., Ganguly B P, Chauhan L N. Comparison of efficacy and safety of two parenteral iron preparations in pregnant women. Journal of Pharmacology and Pharmacotherapeutics. 2012;3(4): 314-19.
13. Kharde P S, Bangal V B, Panicker K K. Comparative study of intravenous iron sucrose versus oral iron therapy in iron deficiency anemia during postpartum period. IJBAR 2012; 03:08.
14. Lyseng-Williamsom KA, Keating GM. Ferric carboxymaltose: areview of its use in iron-deficiency anaemia. Drugs.2009;69(6):739–56.25.
15. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–92.
16. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med.2009;361(25):2436–48.
17. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion.2009;49(12):2719–28.
18. Covic A, Mircescu G. The safety and efficacy of intravenous iron carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25(8):2722–30.29. Macdougall L, Chappeli J, Chai MO. Iron supplementation.
19. Yaqoob N, Abbasi SM. Nutritional iron deficiency in our population. J Coll Physicians Surg Pak 2002; 12: 395-7.
20. Bayoumeu F, Subiran-Bursset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gyneco). 2002:186:5\8-22.
21. Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol. 2009:144:135-9.
22. Breymann C, Honegger C, Holzgreve W. Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 201 0;282:577-80.
23. Khalafallah A, Dennis A, Bates. l, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med. 2010;268:286-95.
24. Malek A. In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta. Arzneimittelforschung. 2010;60:354